tiprankstipranks
Advertisement
Advertisement
Viridian Initiated at Buy as Lumivoa FDA Approval Transitions Company to Commercial Stage; $35 Price Target Reiterated
PremiumRatingsViridian Initiated at Buy as Lumivoa FDA Approval Transitions Company to Commercial Stage; $35 Price Target Reiterated
1M ago
Wells upgrades Viridian Therapeutics as Lumvoa launch KPIs likely to outperform
Premium
The Fly
Wells upgrades Viridian Therapeutics as Lumvoa launch KPIs likely to outperform
1M ago
Viridian Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
Premium
The Fly
Viridian Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo
1M ago
Viridian Therapeutics Fully Repays Loan, Ends Agreement
PremiumCompany AnnouncementsViridian Therapeutics Fully Repays Loan, Ends Agreement
2M ago
Viridian Therapeutics secures WuXi deal for veligrotug manufacturing
Premium
Company Announcements
Viridian Therapeutics secures WuXi deal for veligrotug manufacturing
2M ago
Viridian Therapeutics price target lowered to $26 from $27 at Evercore ISI
Premium
The Fly
Viridian Therapeutics price target lowered to $26 from $27 at Evercore ISI
3M ago
Viridian Therapeutics: REVEAL-2 Success and Strong Cash Runway Support Buy Rating, $32 Price Target Unchanged
PremiumRatingsViridian Therapeutics: REVEAL-2 Success and Strong Cash Runway Support Buy Rating, $32 Price Target Unchanged
3M ago
Analyst Reiterates Buy as Strong Phase III REVEAL-2 Data Boost Elegrobart’s Regulatory and Commercial Outlook
Premium
Ratings
Analyst Reiterates Buy as Strong Phase III REVEAL-2 Data Boost Elegrobart’s Regulatory and Commercial Outlook
3M ago
Viridian Reports Positive Phase 3 Results in Thyroid Eye Disease
Premium
Company Announcements
Viridian Reports Positive Phase 3 Results in Thyroid Eye Disease
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100